Bayer Gets FDA Priority Review for Finerenone in Diabetes With Chronic Kidney Disease
January 12 2021 - 09:20AM
Dow Jones News
By Colin Kellaher
Bayer AG on Tuesday said the U.S. Food and Drug Administration
granted priority review to finerenone for patients with chronic
kidney disease and type 2 diabetes.
The Leverkusen, Germany, chemical and pharmaceutical company
said finerenone offers a potential new strategy to delay the
progression of chronic kidney disease in people with type 2
diabetes while reducing the risk of cardiovascular events.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review period to
six months from the standard 10 months.
Bayer said there is currently a significant unmet medical need
for the nearly 40% of people in the U.S. with type 2 diabetes who
will develop chronic kidney disease, a progressive condition can
lead to kidney damage and eventual failure.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 12, 2021 09:05 ET (14:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Mar 2023 to Mar 2024